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Cystic Fibrosis (CF) is often accompanied by diabetes leading to worsening lung function, the reason for
which is unclear. The receptor for advanced-glycation-end-products (RAGE) regulates immune responses
and inflammation and has been linked to diabetes and possibly CF. We performed a pilot study to determine
if CF and CF-related diabetes (CFRD) are associated with enhanced RAGE expression. Full length (fl)RAGE,
soluble (s)RAGE, endogenous soluble (es)RAGE, S100A12 (enRAGE) and advanced-glycation-end-products
(AGE) expression was assessed in serum, white blood cells and sputum of patients with CF; diabetes; CFRD
and healthy subjects. Sputum enRAGE/sRAGE ratios were high in CF but particularly in CFRD which
negatively correlated with % predicted FEV1. Serum AGE and AGE/sRAGE ratios were high in diabetics but
not in CF. A complex, multifaceted approach was used to assess the role of RAGE and its ligands which is
fundamental to determining their impact on airway inflammation. There is a clear association between RAGE
activity in the airways of CF and CFRD patients that is not evident in the vascular compartment and correlates
with lung function, in contrast to diabetes. This strongly suggests a role for RAGE in contributing to the
inflammatory overdrive seen in CF and to a greater extent in CFRD.
C
ystic fibrosis (CF) is the most common autosomal recessive condition in Caucasians and is associated with
bronchiectasis, airway inflammation and an increase in diabetes1. Cystic Fibrosis Related Diabetes
(CFRD) prevalence increases with age; with more than 50% of CF patients having diabetes by age 40.
CFRD patients have a higher mortality than CF alone and there is a strong association between CFRD and
deterioration in lung function and clinical status2. Why diabetes should do this is unknown.
The receptor for advanced glycation end products (RAGE) is a member of the immunoglobulin superfamily of
cell surface molecules. The receptor is membrane bound and is also known as full length (fl)RAGE or membrane
RAGE (mRAGE). It is a multi-ligand receptor and regarded as a central mediator in chronic inflammatory and
immune responses3. RAGE is found in human airways with high basal levels of RAGE expressed in pulmonary
tissue4. It is also found on pro-inflammatory and immuno-competent cells such as neutrophils, monocytes,
macrophages, and T and B lymphocytes3,5.
RAGE binds a broad range of ligands associated with inflammatory responses, including advanced glycation
end products (AGE), b-sheet fibrillary structures (b-amyloid & serum amyloid A), amphoterin (HMGB1) and
members of the S100/calgranulin family (such as S100A12 also known as enRAGE)3,5,6. EnRAGE is secreted by
activated granulocytes and is a marker of inflammation in CF7. These ligands, as well as activating RAGE, also up-
regulate RAGE production and thereby perpetuate the inflammatory response due to downstream production of
cytokines, adhesion molecules and matrix metalloproteinases5.
RAGE expression and its signaling are regulated both by its ligands and by RAGE isoforms known collectively
as soluble RAGE (sRAGE). sRAGE contains the extracellular domain of RAGE and can bind to circulating pro-
inflammatory ligands preventing their binding to mRAGE thereby preventing RAGE activation. sRAGE consists
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from the proteolytic cleavage of mRAGE (ectodomain shedding)
from the cell membrane; and 2) alternative splicing of the RAGE
transcript resulting in 10 variants detected in the human lung8,9. Of
these the most significant is an endogenous soluble RAGE (esRAGE).
Importantly decreased levels of esRAGE and/or increases in mRAGE
are thought to enhance RAGE mediated inflammation10.
In healthy adults, serum levels of sRAGE and RAGE ligands are
well matched11. In contrast decreased levels of serum sRAGE is linked
to atherosclerosis, arthritis and CF6,12,13. Levels are lower in diabetic
patients with complications versus those without3. Diabetes is also
associated with raised AGE levels and subsequent up regulation of
inflammation occurs as a consequence of AGE activation of RAGE3.
The link between RAGE and CF has been reported in only a small
number of studies. CF airway neutrophils have increased RAGE
compared to peripheral blood neutrophils while CF airway fluid
has increased levels of enRAGE and lacks sRAGE the protective
decoy receptor6,7. The association between RAGE, inflammation,
the lung and diabetes suggests that RAGE may have an important
role in CF but particularly in CFRD.
We hypothesized that chronic RAGE activation and resulting
increased airway inflammation leads to worsening lung function
and clinical status in CFRD compared to non-diabetic CF patients.
To address this we quantified RAGE expression in induced sputum,
peripheral blood leukocytes (PBLs) and in serum. sRAGE, esRAGE,
fl/mRAGE, the ligands enRAGE (S100A12) and AGE, were assessed
in CFRD, CF, Diabetics and healthy subjects. We explored the inter-
action of the various elements of the RAGE pathway and correlated
this with lung function.
Table 1 | Clinical Parameters of recruited patients
Characteristic Healthy CF CFRD Diabetic P
Gender (M/F) 4/6 (n 5 10) 4/1 (n 5 5) 2/3 (n 5 5) 5/2 (n 5 7) -
Age (Years) 38.9 6 9.47 31.4 6 9.71 33.6 6 10.88 25.29 6 7.76 0.1079
FEV1/FVC % predicted 81.60 6 8.51 62.59 6 17.99* 60.39 6 9.47* 92.14 6 13.03 0.0002*
BMI (kgm22) 25.5 6 4.06 21.61 6 3.58 30.72 6 21.13 27.46 6 6.01 0.5182
HbA1c (%) - 5.9 6 0.22 6.98 6 0.75* 7.57 6 0.93* 0.0282*
0.0072*
CRP - 12.97 6 4.63 4.57 6 3.32 - 0.063
WCC - 9.57 6 1.86 10.9 6 2.96 - 0.5277
The clinical parameters are shown as mean 6 standard deviation, *statistically significant; M, Male; F, Female; CF, cystic fibrosis; CFRD, cystic fibrosis related diabetes; FEV1/FVC, forced expiratory
volume/forced vital capacity; BMI, body mass index; HbA1c, haemoglobin A1c; CRP, C-reactive protein; WCC, white blood cell count.
Figure 1 | flRAGE and esRAGE mRNA Expression in blood and sputum. The mRNA expression of full length (fl)RAGE and endogenous soluble
(es)RAGE was evaluated by RT-qPCR in total RNA isolated from peripheral blood leucocytes and sputum. Results are shown as Fold increase
representing a relative expression according to the levels of expression in healthy controls. (n $ 5); * p , 0.05; **p , 0.01; ***, 0.001.
www.nature.com/scientificreports
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Results
Clinical parameters. All patients were categorized into one of four
groups: CF, Diabetes (type 1, insulin dependent), CFRD or healthy
controls and their diagnoses confirmed by a specialist physician. The
subject clinical characteristics are provided in Table 1. Five patients
in each group were sequentially selected for sputum analysis.
Induced sputum cell counts. Sputum differential cell counts in
CF and CFRD subjects showed predominantly neutrophils (high
cellularity), while healthy subjects had predominantly macrophages
(low cellularity) and diabetics mixed macrophages/neutrophils (low
cellularity).
mRNA expression of RAGE in peripheral blood leukocytes and in
sputum. The mRNA expression of fl/mRAGE and esRAGE (splice
variant) in PBLs of healthy controls, CF and CFRD patients were
similar, while it was down-regulated in diabetic patients (esRAGE p
, 0.05)(Fig. 1).
In sputum, the mRNA for fl/mRAGE and esRAGE were markedly
overexpressed in CF compared to both healthy individuals (p , 0.01
for fl/mRAGE; p , 0.05 for esRAGE) and diabetics (p , 0.001 for fl/
mRAGE; p , 0.01 for esRAGE). Down-regulation of both RAGE
isoforms at the mRNA level was observed in diabetes compared to
healthy individuals, (p . 0.05). fl/mRAGE and esRAGE mRNA were
overexpressed in CFRD patients to a lesser extent than in the in
sputums of CF only group (p . 0.05) (Fig. 1).
RAGE immunocytochemistry. Fl/mRAGE immunocytochemistry
of sputum showed expression in a range of cell types. Healthy
individuals showed fl/mRAGE predominantly in macrophages with
strong granular diffuse cytoplasmic staining, while no membrane
staining was seen (Fig. 2). Diabetics had fl/mRAGE expression in
macrophages, neutrophils and lymphocytes. Cytoplasmic staining
was similar to healthy patients, but membrane staining was signifi-
cantly higher in diabetics than in healthy subjects (p , 0.05; Fig. 2E).
In CF fl/mRAGE expression on neutrophils was evident in 5/5
subjects and in 4/5 CFRD subjects. For both CF and CFRD pa-
tients, neutrophil fl/mRAGE expression was apparent on the mem-
branes and diffuse in cytoplasm. However, the CFRD group had
significantly less fl/mRAGE staining in the cytoplasm and cell
Figure 2 | flRAGE protein expression in sputum samples from A: Healthy individuals, B: Diabetic subjects, C: cystic fibrosis (CF) and D: CF Related
Diabetic (CFRD) subjects. The immunohistochemical expression is identified predominantly in macrophages in healthy and in diabetic subjects
(A and B), while full lenght (fl)RAGE expression is predominantly identified within the cytoplasm of neutrophils in CF and CFRD subjects (C and D).
Graph represents total intensity of cell staining in the cytoplasm and membranes in healthy, CF, CFRD and diabetic patients assessed according to
Remmele’s sliding scale (E). * p , 0.05; **p , 0.01; ***, 0.001.
www.nature.com/scientificreports
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Figure 3 | Expression of RAGE isoforms and its ligands in serum and sputum a) Expression of RAGE ligands in serum and sputum. The levels of enRAGE
and AGE were assessed using ELISA. b). Expression of soluble RAGE isoforms in serum and sputum. The levels of endogenous soluble (es)RAGE and
soluble (s)RAGE were assessed using ELISA in duplicates. The line in the scatter plots indicates the Mean 6 SEM for each assay. (n $ 5). * p , 0.05; **p ,
0.01; ***, 0.001.
www.nature.com/scientificreports
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membranes than the CF alone group (p , 0.05). A small number of
eosinophils and lymphocytes were observed in the CF subjects and
these showed fl/mRAGE expression; and this was localized predo-
minantly to the cell membrane (Fig. 2). When all cells were assessed
collectively, cell-membrane staining in CF patients was significantly
higher than in healthy (p , 0.001), diabetic (p , 0.05) and CFRD
patients (p , 0.05).
sRAGE, AGE and enRAGE Protein Expression in sputum and
serum. sRAGE protein levels, as well as RAGE ligands (AGE and
enRAGE) were measured in sputum and in serum. Not surprisingly
serum sRAGE, esRAGE, AGE and enRAGE did not differ signi-
ficantly among any disease group or healthy patients (Fig. 3a and 4b).
Sputum AGE concentrations were higher in diabetics than in
healthy subjects (p , 0.05), CF (p , 0.001) and CFRD patients (p
, 0.001) (Fig. 3a). Although sputum enRAGE concentrations in CF
and CFRD patients were decreased compared to healthy and diabetic
patients there was only a statistical difference evident for CF versus
diabetics (p , 0.05) (Fig. 3a).
esRAGE concentrations were lower in CFRD sputa than in healthy
(p , 0.05) and diabetic samples (p , 0.05) (Fig. 3b). Sputum sRAGE
concentrations were significantly lower in CF and CFRD patients
compared to healthy subjects (p , 0.05 & p , 0.01, respectively)
while CFRD sRAGE sputum concentrations were also significantly
lower than in diabetics (p , 0.01) (Fig. 3b).
Characterisation of RAGE mRNA expression in disease states. The
magnitude of fl/mRAGE and esRAGE mRNA expression varied in
different tissues. To assess whether serum markers reflect airway
inflammation, RAGE expression in sputum and serum/PBLs were
compared. Differences in fl/mRAGE and esRAGE mRNA expression
were observed for PBLs versus induced sputum cells within the same
subjects. In healthy patients there was less fl/mRAGE and twice as
much esRAGE mRNA in the sputum than in PBLs (p , 0.001 for
both measurements). In CF alone patients, however, both fl/mRAGE
and esRAGE mRNA expression was much greater in sputum cells
than in PBLs (p , 0.001 for both). This increase was of a different
magnitude with esRAGE mRNA level being 6-fold greater than for
flRAGE levels (Fig. 4). In CFRD the increase in esRAGE expression
in sputum v PBLs was of lower magnitude than in CF patients (300X
versus 200X, p , 0.001) (Fig. 5). In Diabetic patients, esRAGE
mRNA expression was similar in sputum and PBLs, but they had
significantly less fl/mRAGE mRNA expression in sputum compared
to PBLs (p , 0.001) (Fig. 4).
The Ratio of Protein expression of AGE and enRAGE to sRAGE.
The ratios of protein expression of pro-inflammatory AGE and
enRAGE and the presumed protective sRAGE were assessed in each
study group. In serum, this ratio was only significantly greater for dia-
betics (for both AGE and enRAGE) and is in keeping with diabetes
being a systemic vascular orientated disease. However in sputum this
ratio was significantly greater for CFRD (enRAGE only) highlighting
the localization of inflammation to the airways in this disease group
(Fig. 5).
Analysis of interaction between sRAGE, AGE, flRAGE in Sputum.
All of the assessed mediators/factors in sputum samples were
compared and there were marked differences between all patient
groups. CF patients were are all characterised by low sRAGE and
AGE levels. Interestingly, patients with diabetes demonstrated
relatively high levels of mRAGE but equally sRAGE and AGE were
also significantly up-regulated. In CFRD all four variables appeared
to be elevated (Fig. 6).
Correlation between AGE, enRAGE, esRAGE and %predicted
FEV1. To assess the degree to which the various RAGE system
components may be contributing to lung function all patient data
for sRAGE, esRAGE and the ratio enRAGE/sRAGE were correlated
with FEV1 as a percentage of predicted value. This was significantly
positively correlated with sRAGE and esRAGE (p 5 0.0017; p 5
0.0026) and negatively correlated with the ratio of enRAGE/
sRAGE (p 5 0.0076) (Fig. 7).
Discussion
CF is characterised by persistent airway inflammation and bronch-
iectasis. Individuals with CF are susceptible to developing diabetes
and accelerated respiratory decline, but the mechanism is unclear.
RAGE and RAGE ligands are linked to chronic inflammatory states
Figure 4 | The expression of flRAGE and esRAGE mRNA in sputum and
peripheral blood white blood cells. Expression of the full length (fl)RAGE
(A) and endogenous soluble (es)RAGE (B) mRNA was assessed by one step
RT-qPCR. Their expression in the sputum was compared to the levels
measured in peripheral blood peripheral blood leucocytes within the same
patient group (n $ 5). * p , 0.05; **p , 0.01; ***, 0.001.
www.nature.com/scientificreports
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and we hypothesised that collectively they contribute to the
rapid decline in lung function seen in CFRD. In this study we
have demonstrated that the balance between protective sRAGE
and pro-inflammatory RAGE ligands is adversely affected in patients
with CF and considerably more so in CFRD and is potentially assoc-
iated with worse lung function. Evaluating the balance between pro-
tective sRAGE, fl/mRAGE and RAGE ligands to determine the
impact on inflammation seemed fundamental while peripheral blood
assessments were likely to be relatively insensitive to the role of
RAGE in airway diseases compared to diabetes.
This is the first study to characterize differences in expression of
RAGE and its ligands in both serum and sputum in CF and diabetes.
Although CF patients failed to show any difference in serum ligand/
RAGE expression (compared to normals) they did have marked up-
regulation of fl/mRAGE, down-regulation of sRAGE and high AGE/
sRAGE ratios in sputa. The CFRD patients differed with the non-
diabetic CF patients in several aspects. They had less fl/mRAGE
detected in sputum cells and had a further reduction in protective
sRAGE. Most importantly, in CFRD the ratio of enRAGE/sRAGE in
sputum was considerably higher than in any other patient group
making them more vulnerable to increased inflammatory insult.
For diabetic patients there was a much higher proportion of serum
enRAGE (and AGE) than protective sRAGE compared to healthy
controls. This ratio strikingly differentiated diabetic patients from
the other disease groups and importantly healthy subjects.
The serum level of circulating sRAGE in healthy subjects was sim-
ilar to that previously reported14. Interestingly, the serum sRAGE and
esRAGE levels did not differ significantly between patient groups. Low
serum levels of sRAGE have been reported to be associated with a
number of human diseases including diabetes6,15. Plasma sRAGE has
been promoted as a biomarker of acute lung injury and acute pulmo-
nary inflammatory response16. However in our study of more chronic
airway diseases serum sRAGE is not sensitive to disease activity.
Understandably in acute settings initial levels of sRAGE may be
increased, while in chronic disease it may revert to being normal.
RAGE ligands, AGE and enRAGE, are increased in the plasma/serum
in various diseases, including CF and diabetes6,7,17. However, in this
study, although serum enRAGE from diabetic patients was increased
substantially it did not differ from healthy subjects statistically, pos-
sibly due to the small sample size. Increased serum RAGE was not
seen in CF and CFRD patients, indicating a need to reassess whether
changes in serum RAGE levels are informative in chronic airway
inflammatory diseases.
CF and CFDR patients differed significantly from controls and
diabetics with respect to both sputum RAGE and ligand concentra-
tions. In particular fl/mRAGE as well as the ratio between pro-
inflammatory enRAGE and protective sRAGE were increased.
sRAGE and esRAGE were significantly lower in CF and CFRD
patient sputa, than in healthy controls while CFRD patients had
much lower levels than diabetics. The sRAGE levels in CF sputa were
lower than previously reported6. However in that study, only 2/20
patients had detectable sRAGE levels while in this study sRAGE was
detected in 9/10 CF patients and in 4/5 healthy subjects. This
increased detection rate probably reflects differences in induced spu-
Figure 5 | The ratio of AGE/enRAGE and sRAGE in serum and sputum. The levels of soluble (s)RAGE, enRAGE and advance glycation end products
(AGE) were assessed in serum and sputum by ELISA. The ratio of enRAGE/sRAGE and AGE/sRAGE was calculated for serum and sputum for each
patient and grouped based on disease status. (n 5 5). * p , 0.05; **p , 0.01; ***, 0.001.
www.nature.com/scientificreports
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tum protocols and assay conditions. sRAGE is thought to be protect-
ive and corresponds to the extracellular domain of full length
RAGE18. Thus despite an overexpression of mRNA for esRAGE in
sputa, the protein concentrations of sRAGE and esRAGE were lower
in CFRD and CF patients compared to controls. Although this might
reflect alteration to post transcriptional or translational regulation, it
is more likely due to increased binding to ligands and also explains
the low AGE levels seen. Thus the lower levels of sRAGE and
esRAGE (acting as inhibitory decoy receptors) may indirectly con-
tribute to inflammation seen in CF/CFRD by facilitating ligand bind-
ing to fl/mRAGE. The concept of sRAGE being protective is
supported by increased sRAGE and decreased enRAGE/sRAGE spu-
tum ratios correlating with %predicted FEV1. Furthermore, the per-
centage of sputa cells expressing fl/mRAGE and the magnitude of
Figure 6 | Expression of membrane flRAGE (mRAGE), sRAGE, AGE and enRAGE in induced sputum of patients in all disease groups. Radar graph
displays levels of membrane-bound (m)RAGE, soluble (s)RAGE, advance glycation end products (AGE) and enRAGE expression for each patient in
Healthy, CF, CFRD and Diabetes group. Each mediator is presented on the appropriate scale; mRAGE (0-3, green line and numbers) enRAGE (0-6000,
blue line and numbers); AGE (0-10, red line and numbers) and sRAGE (0-1400, yellow line, black numbers), with highest numbers being in the centre of
the graph.
Figure 7 | Correlation between FEV1%pred and mediators in sputum. Graph represents the correlation between FEV1%predicted and a) endogenous
soluble (es)RAGE b) soluble (s)RAGE and c) ratio of enRAGE/sRAGE in sputum of patients.
www.nature.com/scientificreports
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expression was highest in CF and CFRD patients and was predomi-
nantly in neutrophils. Since the antibodies used cannot differentiate
between sRAGE and fl/mRAGE, it is difficult to be certain which
form is being detected in the cytoplasm. However increased mem-
brane bound fl/mRAGE was seen in all CF patients and to a lesser
extent in CFRD and diabetics, but was totally absent in healthy
individuals. This shift in fl/mRAGE localisation represents a greater
risk of disease promotion, as fl/mRAGE can be easily activated by
RAGE ligands particularly when associated with low sRAGE.
Amongst the specific ligands for RAGE are AGEs, a heterogeneous
class of compounds produced by glycation and oxidation of proteins
and lipids. Many S100 calcium binding proteins also bind RAGE
including enRAGE that binds only to RAGE. This is the first study
to assess enRAGE and AGE levels in induced sputum in healthy
volunteers, diabetics, CF and CFRD. However it is inappropriate to
look at them in isolation; it is more logical to assess them relative to
both sRAGE and membrane bound fl/mRAGE. The higher enRAGE/
sRAGE ratio in CFRD patients compared to diabetics and healthy
subjects is almost certainly impacting on the pro-inflammatory envir-
onment of the CF-diabetic airway. In the blood compartment of the
diabetic patients there was an increase in enRAGE/sRAGE and AGE/
sRAGE ratios supporting this being a useful index for monitoring
inflammatory activity in diabetics. Determining the ratio of sRAGE
to mRAGE would also be useful but currently is difficult to quantify.
Our study highlights the need for a complex analysis of data when
investigating the role of RAGE in disease. Diabetes is a systemic disease
and serum levels appear to be relevant while in contrast, measurements
of serum RAGE appeared to have little merit in CF patients. Although
we have shown that sputa data appears to be reflective of airway disease,
it is a challenge to evaluate the relative impact of one component of the
RAGE system over another and the interactions occurring. Therefore in
assessing the sputa data we integrated all of the RAGE components in
our analysis. This is quite different to previous studies which have
simply assessed components in isolation. There were clear differences
between patient groups. CF patients were unmistakably identifiable
from healthy and diabetic patients as demonstrated in Figures 6 and
7. The ratio between enRAGE/sRAGE and AGE/sRAGE in sputa
strongly supports RAGE contributing to the increased lung deteriora-
tion seen in the CFRD group, despite single mediator analysis not
demonstrating this. This data questions the merit of only measuring
AGE and enRAGE levels rather than their ratios with sRAGE.
This was a cross sectional study and this created its own limita-
tions in terms of interpreting RAGE dynamics in patients. Future
studies should aim to assess RAGE expression in patients when stable
and unwell and over a number of time points, but this was outside the
scope of the current study.
The role of RAGE in CF and CFRD is complex. This is a pilot study
and describes the differences in the RAGE pathway in blood and
sputa in CF with and without diabetes, in diabetics and in healthy
subjects and establishes that an association between RAGE related
inflammation and the inflammatory overdrive seen in CF lung dis-
ease is likely. Alterations in the expression of key mediators of the
RAGE pathway specific to CFRD were demonstrated and represent a
plausible explanation for the deterioration in lung function seen in
CFRD. This study uses a complex, multifaceted approach to assess
the role of RAGE in CF that is applicable to other chronic airway
diseases and helps identify the respective contributions of protective
sRAGE, membranous RAGE and RAGE ligands on airway inflam-
mation and their capacity to act as disease biomarkers. Further
assessment of RAGE activation will provide greater clarity as to the
relative importance of the various components of the RAGE system
and open up the potential for new therapies.
Methods
All methods described within the manuscript complied with the MIBBI guidelines
where appropriate.
Patient recruitment. The study was approved by the Human Research Ethics
committee of Sir Charles Gairdner Hospital (SCGH). Patients were recruited
randomly from the SCGH adult CF clinic, SCGH diabetes clinic and the Lung
Institute of Western Australia Clinical Trials Unit. Written informed consent was
obtained from all participants and the methods carried out complied with the
approved guidelines.
Sputum induction, processing and immunolabelling for RAGE receptor.
Spontaneous sputum was collected from CF and CFRD patients and sputum
induction performed on diabetic and healthy individuals. Sputum induction followed
a standard protocol19, with a 4.5% saline solution inhaled for a total of 15.5 min from
an ultrasonic nebulizer (Ultraneb 2000, PA, USA) after measurement of baseline
FEV1. FEV1 was measured at 30 sec, 1 min, 2 min, and three 3 4 min and subjects
were encouraged to expectorate sputum.
All collected sputum samples were solubilised with 4 vol. of 0.1 % dithiothreitol and
after centrifugation (400 g, 10 min), the cell-free supernatant was stored at 280uC
for RAGE assay analysis. The cell pellet was resuspended in phosphate-buffered saline
(PBS) and the total cell count and cell viability was assessed. Cytospins were prepared
and stored in the dark at room temperature. Cytospins were fixed in acetone-meth-
anol (151). After rehydration (0.01 M PBS, pH 7.4) peroxidase activity was inhibited
with peroxidase block (DAKO, Sydney, Australia) for 5 min. Non-specific protein
binding was blocked with 20% swine serum and serum-free protein block (DAKO,
Sydney, Australia) for 15 min each. Slides were then incubated with RAGE antibody
(Abcam, Cambridge, UK) at a dilution of 1/100 in 0.01 M PBS containing 1% bovine
serum albumin (BSA) overnight at room temperature following incubation with anti-
rabbit horseradish peroxidase conjugated polymer (DAKO, Sydney, Australia) for
30 min at room temperature. Labelling was visualized by incubating the slides with
3,39-diaminobenzidine (DAB), counter staining with Mayer’s haematoxylin and
differential white cell staining (Diff-Quick stain). The specificity of immuno-labelling
was verified by negative control slides from which the primary antibody was omitted.
Assessment of sputum differential cell count and flRAGE expression staining was
undertaken. Staining was assessed by two observers independently. A positive result
was assigned when diffusely cytoplasmic or strong membranous staining was
observed in leukocytes. Staining intensity was graded semi-quantitatively based on
Remmele’s sliding scale: negative (0), weak (1), moderate (2) and strong (3)20
Intensity values of scores 2 and 3 were considered to represent positive flRAGE
expression. In discrepant cases a consensus opinion was reached.
Separation of peripheral blood leukocytes. Whole blood was collected in EDTA and
passed through LeukoLOCK filters (LeukoLOCK Total RNA Isolation System,
Ambion Inc. USA). The filters captured the total leukocyte population, while plasma,
platelets and red blood cells were eliminated. The filters were flushed with PBS to
remove residual red blood cells and then with RNAlater (LeukoLOCK) to stabilize
leukocyte RNA. Filters were sealed and stored at -80uC until further processing.
RNA isolation. LeukoLOCK filters were thawed to RT for 5 min and flushed with
TRIzol Reagent (Life Technologies, Australia). RNA was separated into aqueous phase
by chloroform and total RNA isolated using PureLink RNA Mini Kit (Life
Technologies). Total RNA from sputum cells was extracted using RNeasy Mini kit
(Qiagen, Australia).
Real time PCR. Fl/mRAGE and esRAGE mRNA expression in blood and sputum
were assessed by quantitative real-time PCR (StepOnePlus, Applied Biosystems,
Australia) using flRAGE (HS00542592_G1) and soluble esRAGE (HS00542584_G1)
specific primer-probes (Applied Biosystems), using the QuantiTect primer-probe One
Step RT PCR kit (Qiagen). Cycle conditions were 50uC for 20 min; 95uC for 15 min;
45 cycles of 95uC for 1s and 60uC for 1 min. Each sample was run in triplicate and
relative expression levels calculated by normalising the targets to the endogenously
expressed housekeeping gene human peptidylpropyl isomerase A.
Elisa. Concentrations of RAGE were determined in serum and sputum using ELISA
kits sRAGE (R&D Systems, USA), esRAGE (B-Bridge International, USA) and the
RAGE ligands: enRAGE (CircuLex, USA) and AGEs (Cell Biolab, USA), using
standard protocols.
Statistical analysis. Data are presented as mean 6 Standard Error of the Mean
(SEM). GraphPad Prism (San Diego, USA) was used for data analysis. ANOVA
followed by multiple comparisons testing using Tukey’s test was used to determine
significant differences between group means. In all instances, a P value less than 0.05
was considered significant.
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